MEDICINOVA INC (MNOV) Stock Price, Quote, News and Overview
NASDAQ:MNOV - Nasdaq - US58468P2065 - Common Stock - Currency: USD
MNOV Quote, Performance and Key Statistics
NASDAQ:MNOV (4/24/2025, 8:26:30 PM)
1.54
+0.05 (+3.36%)
The current stock price of MNOV is 1.54 USD. In the past month the price increased by 4.76%. In the past year, price increased by 17.56%.
MNOV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 23.03 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About MNOV
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Company Info
MEDICINOVA INC
Suite 650, 4275 Executive Square
La Jolla CALIFORNIA 92037 US
CEO: Yuichi Iwaki
Employees: 13
Company Website: https://medicinova.com/
Investor Relations: https://investors.medicinova.com
Phone: 18583731500
MEDICINOVA INC / MNOV FAQ
What is the stock price of MEDICINOVA INC today?
The current stock price of MNOV is 1.54 USD. The price increased by 3.36% in the last trading session.
What is the ticker symbol for MEDICINOVA INC stock?
The exchange symbol of MEDICINOVA INC is MNOV and it is listed on the Nasdaq exchange.
On which exchange is MNOV stock listed?
MNOV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MEDICINOVA INC stock?
8 analysts have analysed MNOV and the average price target is 8.5 USD. This implies a price increase of 451.95% is expected in the next year compared to the current price of 1.54. Check the MEDICINOVA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDICINOVA INC worth?
MEDICINOVA INC (MNOV) has a market capitalization of 75.54M USD. This makes MNOV a Micro Cap stock.
How many employees does MEDICINOVA INC have?
MEDICINOVA INC (MNOV) currently has 13 employees.
What are the support and resistance levels for MEDICINOVA INC (MNOV) stock?
MEDICINOVA INC (MNOV) has a support level at 1.25 and a resistance level at 1.54. Check the full technical report for a detailed analysis of MNOV support and resistance levels.
Should I buy MEDICINOVA INC (MNOV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MNOV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MNOV, evaluating the profitability, health, valuation and growth aspects
- MEDICINOVA INC (MNOV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDICINOVA INC (MNOV) Sales and EPS estimates to see what analysts future expectations are.
- MEDICINOVA INC (MNOV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDICINOVA INC (MNOV) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDICINOVA INC (MNOV) Stock Chart to make your own analysis
- MEDICINOVA INC (MNOV) Latest news and press-releases to stay up to date.
Does MEDICINOVA INC (MNOV) stock pay dividends?
MNOV does not pay a dividend.
When does MEDICINOVA INC (MNOV) report earnings?
MEDICINOVA INC (MNOV) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of MEDICINOVA INC (MNOV)?
MEDICINOVA INC (MNOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of MEDICINOVA INC (MNOV) stock?
The outstanding short interest for MEDICINOVA INC (MNOV) is 0.57% of its float. Check the ownership tab for more information on the MNOV short interest.
MNOV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MNOV. When comparing the yearly performance of all stocks, MNOV turns out to be only a medium performer in the overall market: it outperformed 60.02% of all stocks.
MNOV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNOV. No worries on liquidiy or solvency for MNOV as it has an excellent financial health rating, but there are worries on the profitability.
MNOV Financial Highlights
Over the last trailing twelve months MNOV reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -27.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.78% | ||
| ROE | -21.05% | ||
| Debt/Equity | 0 |
MNOV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MNOV. The Buy consensus is the average rating of analysts ratings from 8 analysts.